Related Experiment Video
Updated: May 25, 2026

07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Recent advances in non-rhabdomyosarcoma soft-tissue sarcomas
1University of Texas, MD Anderson Cancer Center, Houston, Texas, USA. ahJordan@mdanderson.org
Seminars in Pediatric Surgery
|January 18, 2012
Summary
This review focuses on pediatric nonrhabdomyosarcoma soft-tissue sarcomas (NRSTS), detailing advances in diagnosis, surgical management, and treatment. Achieving adequate surgical local control is crucial for preventing recurrence in these rare childhood cancers.
Area of Science:
- Pediatric Oncology
- Surgical Oncology
- Sarcoma Research
Background:
- Nonrhabdomyosarcoma soft-tissue sarcomas (NRSTS) comprise over 50 rare pediatric cancer histologies.
- While management often overlaps, specific NRSTS require tailored approaches in young patients.
- This review highlights NRSTS most prevalent in pediatric and adolescent populations.
Purpose of the Study:
- To review recent diagnostic and therapeutic advances for pediatric NRSTS.
- To emphasize the critical role of surgical local control in managing these rare tumors.
- To focus on NRSTS with unique management considerations in young patients.
Main Methods:
- Literature review of recent advances in NRSTS diagnosis.
- Analysis of surgical management strategies for primary NRSTS.
- Examination of current treatment protocols and their impact on recurrence.
Main Results:
- Surgical local control is a key determinant of both local and distant recurrence.
- Advances in diagnosis aid in better classification and targeted treatment.
- Multidisciplinary approaches are essential for optimal outcomes in pediatric NRSTS.
Conclusions:
- Effective surgical local control is paramount for improving outcomes in pediatric NRSTS.
- Continued research into diagnosis and treatment is vital for this rare group of cancers.
- Tailored management strategies are necessary for specific NRSTS histologies in children and adolescents.
More Related Videos
Related Concept Videos
Rous Sarcoma Virus (RSV) and Cancer
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
RSV is a retrovirus that contains two copies of a plus-strand RNA genome. Its genome consists of four main open...
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...

